Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets

Author(s): Santina Bruzzone, Marco Daniele Parenti, Alessia Grozio, Alberto Ballestrero, Inga Bauer, Alberto Del Rio, Alessio Nencioni

Volume 19, Issue 4, 2013

Page: [614 - 623] Pages: 10

DOI: 10.2174/1381612811306040614

Abstract

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

Keywords: Sirtuin modulators, cancer, drug design, epigenetics, drug discovery


© 2024 Bentham Science Publishers | Privacy Policy